Ahmet Gl

List of Publications by Citations

244 papers	11,116 citations	55 h-index	102 g-index
278 ext. papers	13,358 ext. citations	4.3 avg, IF	6.03 L-index

#	Paper	IF	Citations
244	Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. *Arthritis and Rheumatism*, **2002**, 46, 2121-31		649
243	Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. *Medicine (United States)*, **2005**, 84, 1-11	1.8	495
242	EULAR recommendations for the management of Behçet disease. *Annals of the Rheumatic Diseases*, **2008**, 67, 1656-62	2.4	478
241	Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. *Nature Genetics*, **2010**, 42, 698-702	36.3	475
240	The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. *Annals of the Rheumatic Diseases*, **2010**, 69, 61-4	2.4	399
239	Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. *Nature Genetics*, **2013**, 45, 202-7	36.3	375
238	Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. *Nature Genetics*, **2016**, 48, 67-73	36.3	359
237	2018 update of the EULAR recommendations for the management of Behçet's syndrome. *Annals of the Rheumatic Diseases*, **2018**, 77, 808-818	2.4	277
236	Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. *Arthritis and Rheumatism*, **2004**, 50, 3934-40		255
235	Prevalence of Behçet's disease in Istanbul, Turkey. *International Journal of Dermatology*, **2003**, 42, 803-6	1.7	251
234	Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. *Arthritis and Rheumatism*, **2005**, 52, 2478-84		235
233	Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. *Rheumatology*, **2007**, 46, 736-41	3.9	231
232	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. *New England Journal of Medicine*, **2018**, 378, 1908-1919	59.2	214
231	Behçet's disease as an autoinflammatory disorder. *Inflammation and Allergy: Drug Targets*, **2005**, 4, 81-3		181
230	Interleukin-1β regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. *Annals of the Rheumatic Diseases*, **2012**, 71, 563-6	2.4	173
229	Pulmonary manifestations of Behçet's disease. *Thorax*, **2001**, 56, 572-8	7.3	162
228	Classification criteria for autoinflammatory recurrent fevers. *Annals of the Rheumatic Diseases*, **2019**, 78, 1025-1032	2.4	159

227	Induced-Pluripotent-Stem-Cell-Derived Primitive Macrophages Provide a Platform for Modeling Tissue-Resident Macrophage Differentiation and Function. *Immunity*, **2017**, 47, 183-198.e6	32.3	153
226	Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. *Annals of the Rheumatic Diseases*, **2011**, 70, 2095-102	2.4	146
225	Familial aggregation of Behçet's disease in Turkey. *Annals of the Rheumatic Diseases*, **2000**, 59, 622-5	2.4	134
224	Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **2016**, 75, 1133-8	2.4	134
223	Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. *Annals of the Rheumatic Diseases*, **2009**, 68, 1528-34	2.4	131
222	'MHC-I-opathy'-unified concept for spondyloarthritis and Behçet disease. *Nature Reviews Rheumatology*, **2015**, 11, 731-40	8.1	124
221	Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). *Annals of the Rheumatic Diseases*, **2017**, 76, 942-947	2.4	122
220	COVID-19 is a Real Headache!. *Headache*, **2020**, 60, 1415-1421	4.2	115
219	A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. *Annals of the Rheumatic Diseases*, **2018**, 77, 728-735	2.4	111
218	Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behçet disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 8134-9	11.5	105
217	CT findings of pulmonary artery aneurysms during treatment for Behçet's disease. *American Journal of Roentgenology*, **1999**, 172, 729-33	5.4	105
216	HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 15970-5	11.5	103
215	Immunology and functional genomics of Behçet's disease. *Cellular and Molecular Life Sciences*, **2003**, 60, 1903-22	10.3	100
214	Behçet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 8867-72	11.5	95
213	Immunohistology of skin pathergy reaction in Behçet's disease. *British Journal of Dermatology*, **1995**, 132, 901-7	4	93
212	Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet's disease susceptibility. *Nature Genetics*, **2017**, 49, 438-443	36.3	89
211	Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. *Annals of the Rheumatic Diseases*, **2017**, 76, 906-913	2.4	89
210	Whole-genome screening for susceptibility genes in multicase families with Behçet's disease. *Arthritis and Rheumatism*, **2005**, 52, 1836-42		89

209	Coagulation factor V gene mutation increases the risk of venous thrombosis in behçet's disease. *Rheumatology*, **1996**, 35, 1178-80	3.9	83
208	Pathogenesis of Behçet's disease: autoinflammatory features and beyond. *Seminars in Immunopathology*, **2015**, 37, 413-8	12	79
207	Quality of life changes with canakinumab therapy in adults with colchicine resistant FMF. *Pediatric Rheumatology*, **2015**, 13,	3.5	78
206	Evidence for linkage of the HLA-B locus in Behçet's disease, obtained using the transmission disequilibrium test. *Arthritis and Rheumatism*, **2001**, 44, 239-40		78
205	Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. *Lupus*, **2004**, 13, 274-8	2.6	74
204	Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet's disease. *British Journal of Rheumatology*, **2003**, 42, 860-4		74
203	Adult-onset Still's disease. *International Journal of Clinical Practice*, **2009**, 63, 1050-5	2.9	72
202	Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. *Arthritis Research and Therapy*, **2015**, 17, 243	5.7	71
201	Comparative study of the skin pathergy test with blunt and sharp needles in Behçet's disease: confirmed specificity but decreased sensitivity with sharp needles. *Annals of the Rheumatic Diseases* , **1993**, 52, 823-5	2.4	71
200	Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet uveitis. *Graefeis Archive for Clinical and Experimental Ophthalmology*, **2008**, 246, 1169-77	3.8	66
199	Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. *Seminars in Arthritis and Rheumatism*, **2017**, 47, 115-120	5.3	65
198	Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. *Annals of the Rheumatic Diseases*, **2018**, 77, 1558-1565	2.4	61
197	Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. *Journal of Rheumatology*, **2014**, 41, 1304-10	4.1	60
196	HLA-B*51 and Behçet Disease. *Ocular Immunology and Inflammation*, **2012**, 20, 37-43	2.8	60
195	Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence. *Journal of Rheumatology*, **2016**, 43, 524-9	4.1	58
194	Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. *Rheumatology*, **2018**, 57, 2200-2212	3.9	57
193	Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. *Rheumatology International*, **2012**, 32, 3277-9	3.6	57
192	Linkage mapping of a novel susceptibility locus for Behçet's disease to chromosome 6p22-23. *Arthritis and Rheumatism*, **2001**, 44, 2693-6		56

191	International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. *Arthritis Care and Research*, **2017**, 69, 578-586	4.7	55
190	Genetics of Behçet's disease: lessons learned from genomewide association studies. *Current Opinion in Rheumatology*, **2014**, 26, 56-63	5.3	55
189	A weak association of HLA-B*2702 with Behçet's disease. *Genes and Immunity*, **2002**, 3, 368-72	4.4	55
188	Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. *Rheumatology International*, **2012**, 32, 177-82	3.6	54
187	International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. *Rheumatology*, **2017**, 56, 2102-2108	3.9	54
186	Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). *Annals of the Rheumatic Diseases*, **2016**, 75, 1051-6	2.4	52
185	Use of Gevokizumab in Patients with Behçet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study. *Ocular Immunology and Inflammation*, **2018**, 26, 1023-1033	2.8	50
184	Lack of association of HLA-B*51 with a severe disease course in Behçet's disease. *British Journal of Rheumatology*, **2001**, 40, 668-72		49
183	FMF50: a score for assessing outcome in familial Mediterranean fever. *Annals of the Rheumatic Diseases*, **2014**, 73, 897-901	2.4	48
182	Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: a controlled study. *Rheumatology International*, **2012**, 32, 79-83	3.6	48
181	Perinatal outcomes in severe preeclampsia-eclampsia with and without HELLP syndrome. *Gynecologic and Obstetric Investigation*, **2005**, 59, 113-8	2.5	47
180	Peripheral blood T cell expansions in patients with Behcet's disease. *Clinical and Experimental Immunology*, **1997**, 107, 520-7	6.2	47
179	Inflammatory/demyelinating central nervous system involvement in familial Mediterranean fever (FMF): coincidence or association?. *Journal of Neurology*, **2006**, 253, 928-34	5.5	46
178	Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. *Joint Bone Spine*, **2008**, 75, 299-302	2.9	45
177	Association of familial Mediterranean fever-related MEFV variations with ankylosing spondylitis. *Arthritis and Rheumatism*, **2010**, 62, 3232-6		42
176	Association of Major Histocompatibility Complex Class I Chain-Related Gene A and HLA-B Alleles with Behçet's Disease in Turkey. *Japanese Journal of Ophthalmology*, **2007**, 51, 431-6	2.6	42
175	Procoagulant mutations and venous thrombosis in Behçet's disease. *Rheumatology*, **1999**, 38, 1298-9	3.9	42
174	A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behçet's disease in HLA-B*51 carriers. *Annals of the Rheumatic Diseases*, **2016**, 75, 2208-2211	2.4	42

173	Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. *Rheumatology International*, **2011**, 31, 183-9	3.6	41
172	Pro-inflammatory cellular immune response in Behçet's disease. *Rheumatology International*, **2007**, 27, 1113-8	3.6	40
171	Organizing pneumonia associated with pulmonary artery aneurysms in Behçet's disease. *Rheumatology*, **1999**, 38, 1285-9	3.9	39
170	Ancient familial Mediterranean fever mutations in human pyrin and resistance to Yersinia pestis. *Nature Immunology*, **2020**, 21, 857-867	19.1	38
169	Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. *Seminars in Arthritis and Rheumatism*, **2019**, 48, 752-762	5.3	38
168	Perinatal outcomes of twin pregnancies discordant for major fetal anomalies. *Fetal Diagnosis and Therapy*, **2005**, 20, 244-8	2.4	38
167	Polymorphisms in the endothelial nitric oxide synthase gene are associated with Behçet's disease. *Rheumatology*, **2005**, 44, 614-7	3.9	38
166	Safety and Efficacy of Gevokizumab in Patients with Behçet's Disease Uveitis: Results of an Exploratory Phase 2 Study. *Ocular Immunology and Inflammation*, **2017**, 25, 62-70	2.8	36
165	Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren's syndrome, and Wegener's granulomatosis. *Clinical Rheumatology*, **2005**, 24, 673-6	3.9	33
164	Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. *Lupus*, **2016**, 25, 177-84	2.6	32
163	A comparison of clinical findings of familial Mediterranean fever patients with and without amyloidosis. *Rheumatology International*, **2005**, 25, 442-6	3.6	32
162	Standard and novel therapeutic approaches to Behçet's disease. *Drugs*, **2007**, 67, 2013-22	12.1	31
161	Familial Mediterranean fever and seronegative arthritis. *Current Rheumatology Reports*, **2011**, 13, 388-94	4.9	30
160	Impaired endothelium-dependent flow-mediated dilation in Behçet's disease: more prominent endothelial dysfunction in patients with vascular involvement. *International Journal of Clinical Practice*, **2005**, 59, 777-81	2.9	30
159	Treatment of recurrent perforating intestinal ulcers with thalidomide in Behçet's disease. *Annals of Pharmacotherapy*, **2004**, 38, 808-11	2.9	28
158	Comparison of Disease Characteristics, Organ Damage, and Survival in Patients with Juvenile-onset and Adult-onset Systemic Lupus Erythematosus in a Combined Cohort from 2 Tertiary Centers in Turkey. *Journal of Rheumatology*, **2017**, 44, 619-625	4.1	27
157	Association of the MEFV gene variations with inflammatory bowel disease in Turkey. *Journal of Clinical Gastroenterology*, **2013**, 47, e23-7	3	27
156	Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. *Journal of Rheumatology*, **2015**, 42, 2465-9	4.1	26

155	Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2007**, 14, 133-40	2.7	26
154	Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. *Journal of Rheumatology*, **2017**, 44, 1933-1937	4.1	25
153	Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-Behçet's disease. *Journal of Neuroimmunology*, **2011**, 239, 91-7	3.5	25
152	Predictors of damage and survival in patients with Wegener's granulomatosis: analysis of 50 patients. *Journal of Rheumatology*, **2010**, 37, 374-8	4.1	25
151	Follow-up results of 702 patients receiving tumor necrosis factor-antagonists and evaluation of risk of tuberculosis. *Rheumatology International*, **2010**, 30, 1459-63	3.6	25
150	Expression of KIR and C-type lectin receptors in Behcet's disease. *British Journal of Rheumatology*, **2004**, 43, 423-7		25
149	Primary antiphospholipid syndrome associated with mesenteric inflammatory veno-occlusive disease. *Clinical Rheumatology*, **1996**, 15, 207-10	3.9	25
148	Common genetic susceptibility loci link PFAPA syndrome, Behçet's disease, and recurrent aphthous stomatitis. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 14405-14411	11.5	24
147	The regulation of MEFV expression and its role in health and familial Mediterranean fever. *Genes and Immunity*, **2011**, 12, 497-503	4.4	23
146	Predicting important residues and interaction pathways in proteins using Gaussian Network Model: binding and stability of HLA proteins. *PLoS Computational Biology*, **2010**, 6, e1000845	5	23
145	IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. *Arthritis and Rheumatology*, **2018**, 70, 1319-1330	9.5	22
144	Approach to the patients with inadequate response to colchicine in familial Mediterranean fever. *Best Practice and Research in Clinical Rheumatology*, **2016**, 30, 296-303	5.3	22
143	HSP 60 expression in recurrent oral ulcerations of Behçet's disease. *Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics*, **2010**, 110, 196-200		22
142	Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases. *Clinical Rheumatology*, **2007**, 26, 1913-5	3.9	21
141	Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome. *International Journal of Clinical Practice*, **2004**, 58, 1003-7	2.9	21
140	Re-evaluation of heterogeneity in HLA-B*510101 associated with Behçet's disease. *Tissue Antigens*, **2008**, 72, 347-53		20
139	Association between reduced levels of MEFV messenger RNA in peripheral blood leukocytes and acute inflammation. *Arthritis and Rheumatism*, **2007**, 56, 345-50		20
138	Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases. *Rheumatology International*, **2005**, 25, 211-4	3.6	20

137	Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016. *Journal of Rheumatology*, **2017**, 44, 1750-1753	4.1	18
136	Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a. *Graefeis Archive for Clinical and Experimental Ophthalmology*, **2015**, 253, 457-65	3.8	18
135	Expression of regulatory receptors on T cells and their cytokine production in Behcet's disease. *Arthritis Research and Therapy*, **2013**, 15, R15	5.7	18
134	Effect of Interferon alfa-2a Treatment on Adaptive and Innate Immune Systems in Patients With Behçet Disease Uveitis **2019**, 60, 52-63		17
133	Treatment of familial Mediterranean fever: colchicine and beyond. *Israel Medical Association Journal*, **2014**, 16, 281-4	0.9	17
132	Small bowel mucosal damage in familial Mediterranean fever: results of capsule endoscopy screening. *Scandinavian Journal of Gastroenterology*, **2014**, 49, 1414-8	2.4	16
131	Identification of possible pathogenic pathways in Behçet's disease using genome-wide association study data from two different populations. *European Journal of Human Genetics*, **2015**, 23, 678-87	5.3	15
130	Comparison of perinatal and maternal outcomes of severe preeclampsia, eclampsia, and HELLP syndrome. *Journal of the Turkish German Gynecology Association*, **2011**, 12, 90-6	1.1	15
129	Distribution of common CARD15 variants in patients with sporadic Crohn's disease: cases from Turkey. *Digestive Diseases and Sciences*, **2006**, 51, 706-10	4	15
128	Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014. *Journal of Rheumatology*, **2015**, 42, 2436-41	4.1	14
127	Mitochondrial carrier homolog 1 (Mtch1) antibodies in neuro-Behçet's disease. *Journal of Neuroimmunology*, **2013**, 263, 139-44	3.5	14
126	Low-dose natural human interferon-alpha lozenges in the treatment of Behçet's syndrome. *Rheumatology*, **2009**, 48, 1388-91	3.9	14
125	No association of the TLR2 gene Arg753Gln polymorphism with rheumatic heart disease and Behçet's disease. *Clinical Rheumatology*, **2009**, 28, 1385-8	3.9	14
124	Antibodies reactive with HIV-1 antigens in systemic lupus erythematosus. *Lupus*, **1996**, 5, 120-2	2.6	14
123	Eosinophilia and hyperimmunoglobulinemia E as the presenting manifestations of Wegener's granulomatosis. *Clinical Rheumatology*, **2003**, 22, 333-5	3.9	14
122	Increased IL-23 receptor, TNF- and IL-6 expression in individuals with the IL23R-IL12RB2 locus polymorphism. *Immunology Letters*, **2014**, 160, 96-98	4.1	13
121	Re-evaluation of 129 patients with systemic necrotizing vasculitides by using classification algorithm according to consensus methodology. *Clinical Rheumatology*, **2012**, 31, 325-8	3.9	13
120	Behçet's disease: immunological relevance with arthritis of ankylosing spondylitis. *Rheumatology International*, **2013**, 33, 733-41	3.6	13

119	Evaluation of KIR3DL1/KIR3DS1 polymorphism in Behçet's disease. *Genes and Immunity*, **2016**, 17, 396-399	4.4	12
118	The use of two different Health Assessment Questionnaires in Turkish rheumatoid arthritis population and assessment of the associations with disability. *Clinical Rheumatology*, **1999**, 18, 33-7	3.9	12
117	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor-associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. *Journal of Rheumatology*, **2019**, 46, 429-436	4.1	12
116	Dynamics of Inflammatory Response in Autoinflammatory Disorders: Autonomous and Hyperinflammatory States. *Frontiers in Immunology*, **2018**, 9, 2422	8.4	12
115	Recovery from hypoxia and hypercapnic hypoxia: impacts on the transcription of key antioxidants in the shrimp Litopenaeus vannamei. *Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology*, **2014**, 170, 43-9	2.3	11
114	Amyloid arthropathy mimicking seronegative rheumatoid arthritis in multiple myeloma: case reports and review of the literature. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2009**, 16, 226-31	2.7	11
113	Generation of integration-free induced pluripotent stem cells from a patient with Familial Mediterranean Fever (FMF). *Stem Cell Research*, **2015**, 15, 694-6	1.6	10
112	TNF-alpha antagonist therapy modify the tuberculin skin test response. *Rheumatology International* , **2011**, 31, 1147-51	3.6	10
111	Amyopathic dermatomyositis associated with cervical cancer. *Clinical Rheumatology*, **2001**, 20, 438-40	3.9	10
110	Shared epitope homozygosity' is strongly associated with rheumatoid arthritis in Turkey. Istanbul Rheumatology Study Group. *British Journal of Rheumatology*, **1998**, 37, 1126-8		10
109	Natural killer cells dominate a Th-1 polarized response in Behçet's disease patients with uveitis. *Clinical and Experimental Rheumatology*, **2015**, 33, S24-9	2.2	10
108	Unified Modeling of Familial Mediterranean Fever and Cryopyrin Associated Periodic Syndromes. *Computational and Mathematical Methods in Medicine*, **2015**, 2015, 893507	2.8	9
107	An Algorithm for the Diagnosis of Behçet Disease Uveitis in Adults. *Ocular Immunology and Inflammation*, **2020**, 1-10	2.8	9
106	HLA-B51 negative monozygotic twins discordant for Behçet's disease. *Rheumatology*, **1997**, 36, 922-3	3.9	8
105	Colchicine-induced myopathy in a teenager with familial Mediterranean fever. *Annals of Pharmacotherapy*, **2003**, 37, 1821-4	2.9	8
104	Direct and indirect costs associated with ankylosing spondylitis and related disease activity scores in Turkey. *Rheumatology International*, **2015**, 35, 1473-8	3.6	7
103	The OMERACT Core Set of Domains for Outcome Measures in Behçet Syndrome. *Arthritis Care and Research*, **2020**,	4.7	7
102	The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response. *International Journal of Infectious Diseases*, **2021**, 105, 756-762	10.5	7

101	Phenotypic variability including Behçet's disease-like manifestations in DADA2 patients due to a homozygous c.973-2A>G splice site mutation. *Clinical and Experimental Rheumatology*, **2019**, 37 Suppl 121, 142-146	2.2	7
100	Microscopic colitis in patients with Takayasu's arteritis: a potential association between the two disease entities. *Clinical Rheumatology*, **2016**, 35, 2495-9	3.9	6
99	MEFV gene variations in patients with systemic lupus erythematosus. *Modern Rheumatology*, **2014**, 24, 93-6	3.3	6
98	Recurrent anterior uveitis in Henoch Schonlein's vasculitis. *Rheumatology International*, **2010**, 30, 1377-9	3.6	6
97	Remarkable damage along with poor quality of life in Takayasu arteritis: cross-sectional results of a long-term followed-up multicentre cohort. *Clinical and Experimental Rheumatology*, **2017**, 35 Suppl 103, 77-82	2.2	6
96	The efficacy of anti- IL-1 treatment in three patients with coexisting familial Mediterranean fever and multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2020**, 45, 102332	4	5
95	Comment on the article by Durmus et al. "Clinical significance of MEFV mutations in ankylosing spondylitis". *Joint Bone Spine*, **2010**, 77, 281	2.9	5
94	Systemic necrotizing vasculitides in Turkey: a comparative analysis of 40 consecutive patients. *Rheumatology International*, **2005**, 26, 16-20	3.6	5
93	Monogenic lupus due to spondyloenchondrodysplasia with spastic paraparesis and intracranial calcification: case-based review. *Rheumatology International*, **2020**, 40, 1903-1910	3.6	5
92	Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. *Rheumatology*, **2021**, 60, 3799-3808	3.9	5
91	Autoimmune haemolytic anaemia and thrombocytopaenia in a single-centre cohort of patients with systemic lupus erythematosus from Turkey: clinical associations and effect on disease damage and survival. *Lupus*, **2019**, 28, 1480-1487	2.6	4
90	Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. *Journal of Rheumatology*, **2019**, 46, 1198-1201	4.1	4
89	Serum and urine TNF-like weak inducer of apoptosis, monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus. *Lupus*, **2020**, 29, 379-388	2.6	4
88	Rosai-Dorfman disease with factor XII deficiency. *Clinical Rheumatology*, **2009**, 28, 733-6	3.9	4
87	An unusual overdose of leflunomide in a patient with rheumatoid arthritis. *Annals of Pharmacotherapy*, **2004**, 38, 1320-1	2.9	4
86	Clinical course of ocular Behçet's disease in siblings. *Ocular Immunology and Inflammation*, **2001**, 9, 111-24	1.8	4
85	Clinical course of abdominal aortic aneurysms in Behçet disease: a retrospective analysis. *Rheumatology International*, **2019**, 39, 1061-1067	3.6	3
84	Behçet Disease **2019**, 647-665		3

83	Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis. *Rheumatology International*, **2009**, 29, 365-70	3.6	3
82	Comparison of argon laser photocoagulation-induced cutaneous inflammation and skin pathergy test in Behçet's disease. *Clinical Rheumatology*, **2010**, 29, 59-63	3.9	3
81	Prenatal diagnosis of bilateral ventriculocoronary fistulas with hypoplasia of the left ventricle. *Journal of Ultrasound in Medicine*, **2008**, 27, 1111-6	2.9	3
80	Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis. *Rheumatology International*, **2008**, 28, 959-64	3.6	3
79	Molecular dynamics simulations provide molecular insights into the role of HLA-B51 in Behçet's disease pathogenesis. *Chemical Biology and Drug Design*, **2020**, 96, 644-658	2.9	3
78	Inflammatory status might direct ILC and NK cells to IL-17 expressing ILC3 and NK subsets in Behcet's disease. *Immunology Letters*, **2021**, 235, 1-8	4.1	3
77	Genetics of Behçet's Disease **2010**, 265-276		3
76	Pseudodominance of autoinflammatory disease in a single Turkish family explained by co-inheritance of haploinsufficiency of A20 and familial Mediterranean fever. *Clinical and Experimental Rheumatology*, **2019**, 37 Suppl 121, 89-92	2.2	3
75	Prenatal diagnosis and postnatal outcome of persistent right ductus arteriosus: a report of three cases. *Journal of Medical Ultrasonics (2001)*, **2015**, 42, 571-4	1.4	2
74	The rate and significance of type 1/type 2 serum amyloid A protein gene polymorphisms in patients with ankylosing spondylitis and amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2015**, 22, 207-8	2.7	2
73	A novel TNFRSF1 gene mutation in a Turkish family: a report of three cases. *Clinical Rheumatology*, **2013**, 32 Suppl 1, S83-5	3.9	2
72	Letter: is pneumococcal vaccination safe during the COVID-19 pandemic?. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 919-920	6.1	2
71	Reinfection with SARS-CoV-2 in a kidney transplant recipient. *Transplant Infectious Disease*, **2021**, 23, e13695	2.7	2
70	FRI0479 Efficacy of Colchicine and IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever: A Retrospective Analysis. *Annals of the Rheumatic Diseases*, **2016**, 75, 611.3-612	2.4	2
69	THU0303 THE OMERACT CORE DOMAIN SET FOR CLINICAL TRIALS IN BEHÇET'S SYNDROME **2019**,		2
68	Binding stability of peptides on major histocompatibility complex class I proteins: role of entropy and dynamics. *Physical Biology*, **2018**, 15, 026005	3	2
67	Budd-Chiari syndrome in Behçet's disease: a retrospective multicenter study. *Clinical Rheumatology*, **2021**, 1	3.9	2
66	Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls. *Rheumatology International*, **2021**, 1	3.6	2

65	THU0203 Cross-sectional assessment of damage in takayasu arteritis with a validated tool. *Annals of the Rheumatic Diseases*, **2013**, 71, 224.1-224	2.4	1
64	Faible fr□quence dEHLA-B27 chez des patients atteints de spondylarthrite ankylosante en Turquie. *Revue Du Rhumatisme (Edition Francaise)*, **2008**, 75, 433-437	0.1	1
63	Treatment of Libman-Sacks endocarditis by combination of warfarin and immunosuppressive therapy. *Turk Kardiyoloji Dernegi Arsivi*, **2019**, 47, 687-690	0.3	1
62	FRI0502 Biologic Agents in Refractory Adult Still's Disease: Better Response Rates and Acceptable Safety with Anakinra and Tocilizumab. *Annals of the Rheumatic Diseases*, **2016**, 75, 620.1-620	2.4	1
61	Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey. *Journal of Thrombosis and Thrombolysis*, **2021**, 51, 466-474	5.1	1
60	A shared motif of hla-dpb1 affecting the susceptibility to pr3-anca positive granulomatosis with polyangiitis: comparative analysis of a Turkish cohort with matched healthy controls. *Rheumatology International*, **2021**, 41, 1667-1672	3.6	1
59	A single center survey study of systemic vasculitis and COVID-19 during the first months of pandemic. *Turkish Journal of Medical Sciences*, **2021**, 51, 2243-2247	2.7	1
58	Description of damage in different clusters of patients with antiphospholipid syndrome.. *Lupus*, **2022**, 9612033221079781	2.6	1
57	IL-17A and IFN-□are Up-regulated in CD4 and □T Cells in Active Behcet's Disease Patients. *Immunology Letters*, **2021**, 242, 37-37	4.1	0
56	Psychometric validation of Barkley's Adult Sluggish Cognitive Tempo (SCT) Ratings Scale -Turkish version and distinguishing SCT from attention deficit-hyperactivity disorder (ADHD) among Turkish adults.. *Research in Developmental Disabilities*, **2021**, 121, 104155	2.7	0
55	AB0766 SUCCESSFUL TEATMENT OF ANKYLOSING SPONDILITIS ASSOCIATED AA AMYLOIDOSIS WITH SECUKINUMAB: A CASE SERIES WITH THREE PATIENTS. *Annals of the Rheumatic Diseases*, **2021**, 80, 1409.3-1410	2.4	0
54	Long-term follow-up of 89 patients with giant cell arteritis: a retrospective observational study on disease characteristics, flares and organ damage. *Rheumatology International*, **2021**, 41, 439-448	3.6	0
53	A Case of Takayasu Arteritis with Thrombotic Microangiopathy Secondary to Malignant Hypertension Due to Bilateral Renal Artery Stenosis.. *Open Access Rheumatology: Research and Reviews*, **2022**, 14, 39-42	2.4	0
52	Reply to Stoimenis et al. *European Journal of Human Genetics*, **2015**, 23, 1280	5.3	
51	MATHEMATICAL MODELING OF BEHEET'S DISEASE: A DYNAMICAL SYSTEMS APPROACH. *Journal of Biological Systems*, **2015**, 23, 231-257	1.6	
50	FRI0245 Lung Damage in ANCA Associated Vasculitis Assessed by Vasculitis Damage Index: Recurrent Pulmonary Infections Have a Significant Contribution. *Annals of the Rheumatic Diseases*, **2015**, 74, 513.2-513	2.4	
49	AB0896 Cogan Syndrome: Differential Response To Biologic Agents and Role of PET-CT in The Increased Diagnosis of Aortitis. *Annals of the Rheumatic Diseases*, **2016**, 75, 1208.3-1209	2.4	
48	SAT0295 Autoimmune Hemolytic Anemia and Thrombocytopenia in A Single Centre Cohort of Patients with Systemic Lupus Erythematosus from Turkey: Clinical Associations and Effect on Disease Damage and Survival. *Annals of the Rheumatic Diseases*, **2016**, 75, 775.1-775	2.4	

47	AB0595 Favourable Renal Outcome in AAV Nephritis: A CASE Series Reported from A Tertiary Referral Center. *Annals of the Rheumatic Diseases*, **2014**, 73, 1002.1-1002	2.4
46	THU0360 Small Bowel Mucosal Findings in Familial Mediterranean Fever. *Annals of the Rheumatic Diseases*, **2014**, 73, 307.1-307	2.4
45	OP0119 Patient Journey and Treatment Route to Use of First Biologic in Rare Autoinflammatory Diseases: an International Retrospective Chart Review. *Annals of the Rheumatic Diseases*, **2014**, 73, 106.1-106	2.4
44	MEFV gene variations in patients with systemic lupus erythematosus. *Modern Rheumatology*, **2013**, 1	3.3
43	AB0633 A Very High Prevalance of Avascular Necrosis in Turkish Patients with Granulomatosis with Polyangiitis (Wegener's): Preliminary Results from a Single Centre. *Annals of the Rheumatic Diseases* , **2015**, 74, 1110.3-1111	2.4
42	THU0561 Salivary IL-1 Alpha and IL-1 Beta Levels Associated with Oral Mucosal Disease Activity in Behcet's Disease. *Annals of the Rheumatic Diseases*, **2015**, 74, 403.3-404	2.4
41	FRI0279 High Rate and Bimodal Pattern of Severe Infection in a Selected ANCA Associated Vasculitis Cohort. *Annals of the Rheumatic Diseases*, **2015**, 74, 525.3-526	2.4
40	AB1118 Validity and Reliability of Medication Adherence Scale in FMF (Adult Version). *Annals of the Rheumatic Diseases*, **2015**, 74, 1274.3-1275	2.4
39	FRI0442 Acute Phase Reactants and their Correlation with Clinical Activity in Behcet's Disease. *Annals of the Rheumatic Diseases*, **2014**, 73, 547.1-547	2.4
38	Comparison of ultraviolet B-induced cutaneous inflammation and skin pathergy test in Behçet disease. *International Journal of Clinical Rheumatology*, **2013**, 8, 205-211	1.5
37	FRI0210 Poor immunization with hepatitis B vaccination in patients with granulomatosis with poliangiitis (wegener's) and more favorable antibody response in females. *Annals of the Rheumatic Diseases*, **2013**, 71, 385.1-385	2.4
36	Genetic heterogeneity in familial Mediterranean fever: comment on the article by Cazeneuve et al. *Arthritis and Rheumatism*, **2004**, 50, 1355; author reply 1355-6	
35	Initial complete blood count score and predicting disease progression in COVID-19 patients. *American Journal of Blood Research*, **2021**, 11, 77-83	1.6
34	Pulmonary Complications of Behçet's Disease. *Lung Biology in Health and Disease*, **2005**, 377-396	
33	Genetics of Behçet's Disease **2020**, 223-233	
32	AB0485 INVESTIGATION OF PERMANENT ORGAN DAMAGE IN GIANT CELL ARTERITIS: DISEASE FLARES ARE ASSOCIATED WITH INCREASED DAMAGE SCORES. *Annals of the Rheumatic Diseases*, **2020**, 79, 1540.2-1540	2.4
31	SAT0178 HYDROXYCHLOROQUINE CONTROLS DISEASE ACTIVITY IN SLE AND MULTIMODAL IMAGING TECHNIQUES SHOULD BE USED TO DETECT OCULAR TOXICITY. *Annals of the Rheumatic Diseases*, **2020**, 79, 1030.2-1031	2.4
30	AB0486 ANALYSIS OF 89 PATIENTS WITH GIANT CELL ARTERITIS FROM TURKEY: PET-CT AS AN EMERGING METHOD FOR DIAGNOSIS AND HIGH FLARE RATE WITH STANDARD CARE. *Annals of the Rheumatic Diseases*, **2020**, 79, 1540.1-1541	2.4

29	AB0480 AN OPEN-LABEL, EXPLORATORY STUDY TO ESTABLISH THE EFFICACY AND SAFETY OF 1-YEAR CANAKINUMAB TREATMENT IN BEHÇET'S DISEASE PATIENTS WITH NEUROLOGIC OR VASCULAR INVOLVEMENT. *Annals of the Rheumatic Diseases*, **2020**, 79, 1537.3-1538	2.4
28	FRI0160 THE CORRELATION BETWEEN PREGNANCY, DISEASE ACTIVITY AND ADVERSE PREGNANCY OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. *Annals of the Rheumatic Diseases*, **2020**, 79, 664.1-664	2.4
27	SAT0261 FEATURES AND RISK FACTORS OF SERIOUS INFECTIONS IN ANCA ASSOCIATED VASCULITIS: LONG TERM FOLLOW UP OF 186 PATIENTS. *Annals of the Rheumatic Diseases*, **2020**, 79, 1073.1-1073	2.4
26	THU0369 EVALUATION OF DIFFERENT CLASSIFICATION CRITERIA IN SYSTEMIC SCLEROSIS IN A TURKISH COHORT: THE IMPORTANCE OF NON-SKIN MANIFESTATIONS, SEROLOGY AND CAPILLAROSCOPY. *Annals of the Rheumatic Diseases*, **2020**, 79, 416.1-417	2.4
25	SAT0200 RISK FACTORS FOR ADVERSE PREGNANCY OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. *Annals of the Rheumatic Diseases*, **2020**, 79, 1042.1-1042	2.4
24	SAT0346 THE EFFICACY AND SAFETY OF RITUXIMAB IN 27 CASES OF TREATMENT RESISTANT SYSTEMIC SCLEROSIS WITH SEVERE DISEASE ASSESSED BY ACTIVITY SCORES. *Annals of the Rheumatic Diseases*, **2020**, 79, 1119.2-1119	2.4
23	SAT0238 VALIDATION OF THE ADJUSTED GLOBAL ANTIPHOSPHOLIPID SYNDROME SCORE AND CORRELATION WITH EXTRA-CRITERIA MANIFESTATIONS. *Annals of the Rheumatic Diseases*, **2020**, 79, 1062.2-1062	2.4
22	OP0274 CLINICAL ASPECTS, LABORATORY CHARACTERISTICS AND TREATMENT RESPONSES OF AA AMYLOIDOSIS: SINGLE CENTER EXPERIENCE WITH 163 PATIENTS. *Annals of the Rheumatic Diseases*, **2020**, 79, 171.1-171	2.4
21	THU0349 THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND SEVERITY IN SYSTEMIC SCLEROSIS: A PROSPECTIVE ANALYSIS OF 278 PATIENTS. *Annals of the Rheumatic Diseases*, **2020**, 79, 406.2-406	2.4
20	AB0461 ANCA-ASSOCIATED VASCULITIS: CLINICAL FEATURES, RELAPSE, ORGAN DAMAGE AND SURVIVAL IN 197 PATIENTS. *Annals of the Rheumatic Diseases*, **2020**, 79, 1529.1-1529	2.4
19	SAT0343 Utility of Vascular Findings by PET/CT Scan in The Diagnosis and Activity Assessment of Takayasu Arteritis. *Annals of the Rheumatic Diseases*, **2016**, 75, 791.2-791	2.4
18	POS0142 MINIMAL DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS AND ASSOCIATED FACTORS: REAL LIFE DATA FROM A SINGLE CENTER. *Annals of the Rheumatic Diseases*, **2021**, 80, 282.3-283	2.4
17	AB0448 SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: PREDOMINANCE OF PULMONARY FIBROSIS AS A RISK FACTOR FOR MORTALITY IN A SINGLE CENTER COHORT. *Annals of the Rheumatic Diseases*, **2021**, 80, 1251.2-1252	2.4
16	POS1339 MORE FREQUENT AND EARLIER HIP INVOLVEMENT IN SPONDYLOARTHRITIS ASSOCIATED WITH FAMILIAL MEDITERRANEAN FEVER. *Annals of the Rheumatic Diseases*, **2021**, 80, 951.3-952	2.4
15	AB0653 COURSE OF COVID-19 INFECTION IN A SERIES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. *Annals of the Rheumatic Diseases*, **2021**, 80, 1359.1-1359	2.4
14	POS0706 PERFORMANCES OF DIFFERENT CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN A SINGLE CENTER COHORT FROM TURKEY. *Annals of the Rheumatic Diseases*, **2021**, 80, 602.1-603	2.4
13	POS0766 CLUSTER ANALYSIS AND COMPARISON OF CUMULATIVE DAMAGE BY DIAPS IN A SINGLE CENTER COHORT OF APS PATIENTS. *Annals of the Rheumatic Diseases*, **2021**, 80, 636.2-637	2.4
12	POS1259 FAVOURABLE SHORT-TERM COURSE OF COVID-19 IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER USING BIOLOGIC AGENTS. *Annals of the Rheumatic Diseases*, **2021**, 80, 913.2-914	2.4

List of Publications

11	POS1445 RETINOL BINDING PROTEIN 4 AS AN ACUTE PHASE REACTANT AND BIOMARKER IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER AND AMYLOIDOSIS COMPARED TO INFECTIONS. *Annals of the Rheumatic Diseases*, **2021**, 80, 1006.2-1007	2.4
10	AB0331 PULMONARY INVOLVEMENT IN A SINGLE CENTER COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. *Annals of the Rheumatic Diseases*, **2021**, 80, 1191.1-1191	2.4
9	POS0710 ANALYSIS OF 5-YEAR HOSPITALIZATION DATA OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DAMAGE IS A RISK FACTOR FOR FREQUENT AND LONGER STAYS. *Annals of the Rheumatic Diseases*, **2021**, 80, 604.2-605	2.4
8	OP0313 PRELIMINARY CRITERIA FOR MACROPHAGE ACTIVATION SYNDROME ASSOCIATED WITH CORONAVIRUS DISEASE-19. *Annals of the Rheumatic Diseases*, **2021**, 80, 191.1-192	2.4
7	AB0369 EVALUATION OF BASELINE POSITRON EMISSION TOMOGRAPHY IN THE DIAGNOSIS AND ASSESSMENT OF GIANT CELL ARTERITIS. *Annals of the Rheumatic Diseases*, **2021**, 80, 1210.2-1211	2.4
6	POS1257 HYPOGAMMAGLOBULINEMIA IS A SIGNIFICANT RISK FACTOR FOR MORTALITY IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS AND COVID-19. *Annals of the Rheumatic Diseases*, **2021**, 80, 912-913	2.4
5	AB0433 Disease Characteristics, Survival Analysis and Mortality in A Single Centre Cohort of 240 Patients with Antiphospholipid Syndrome. *Annals of the Rheumatic Diseases*, **2016**, 75, 1055.2-1055	2.4
4	The association between P selectin glycoprotein ligand 1 gene variable number of tandem repeats polymorphism and risk of thrombosis in Behçet's disease. *International Journal of Rheumatic Diseases*, **2018**, 21, 2175-2179	2.3
3	Behçet Disease **2018**, 365-370	
2	Reply to: Behçet's disease: an MHC-I-opathy?. *Clinical and Experimental Rheumatology*, **2017**, 35 Suppl 104, 6	2.2
1	The relationship between serum A proliferation-inducing ligand and B-cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus.. *Lupus*, **2022**, 9612033221086123	2.6